Literature DB >> 15581382

Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study.

Robert J Valuck1, Anne M Libby, Marion R Sills, Alexis A Giese, Richard R Allen.   

Abstract

CONTEXT: The US FDA has issued an advisory warning of a possible link between antidepressant treatment for paediatric patients with major depressive disorder (MDD) and an increased risk of suicidal behaviour. A large database of paid health insurance claims for adolescents with MDD provided the opportunity to examine this possible relationship.
OBJECTIVE: To examine the potential empirical link between antidepressant treatment and suicide attempts among adolescents aged 12-18 years using a community sample of managed care enrollees across the US.
DESIGN: A retrospective longitudinal cohort using paid insurance claims for all healthcare and prescription fills for adolescents who were newly diagnosed with MDD and had at least 6 months of follow-up data. A multivariate Cox proportional hazards regression analysis was used to test the hypothesis that antidepressant use increased the risk of suicide attempt, adjusting for propensity for allocation to each treatment group and for demographic and clinical characteristics.
SETTING: Managed care plans including both commercial and Medicaid plans in the east, midwest, south and western regions of the US from January 1997 to March 2003. PARTICIPANTS: All adolescent insurance members aged 12-18 years at first diagnosis of MDD. MAIN OUTCOME MEASURES: Suicide attempts as indicated by medical utilisation with International Classification of Diseases (9th edition) [ICD-9] or 10th edition (ICD-10) codes in any healthcare setting or by any covered provider.
RESULTS: 24 119 adolescents met inclusion criteria (63% female). Crude suicide attempt rates ranged from 0.0-2.3% by index treatment group. Treatment with SSRIs (hazard ratio) [HR] = 1.59; CI 0.89, 2.82), other antidepressants (HR = 1.03; CI 0.43, 2.44), or multiple antidepressants (HR = 1.43; CI 0.70, 2.89) after index MDD diagnosis resulted in no statistically increased risk of suicide attempt. Treatment with antidepressant medication for at least 180 days (6 months) reduced the likelihood of suicide attempt compared with antidepressant treatment for <55 days (8 weeks) [HR = 0.34; CI 0.21, 0.55]. Other variables that were independently associated with greater risk of suicide attempts included female gender, severity of illness indicators, younger age at time of MDD diagnosis, and living in the midwest or west.
CONCLUSIONS: Antidepressant medication use had no statistically significant effect on the likelihood of suicide attempt in a large cohort of adolescents across the US after propensity adjustment for treatment allocation and controlling for other factors. The relationship between suicidal behaviour and antidepressant medication use is complex and requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15581382     DOI: 10.2165/00023210-200418150-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  50 in total

1.  Adolescent suicide: perspectives on a clinical quandary.

Authors:  C R Keith
Journal:  JAMA       Date:  2001-12-26       Impact factor: 56.272

2.  A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization.

Authors:  Robert J Valuck; Setareh A Williams; Marilyn MacArthur; Joseph J Saseen; Kavita V Nair; Marianne McCollum; Joe E Ensor
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

3.  FDA alert on antidepressants for youth.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

4.  British panel bans use of antidepressant to treat children.

Authors:  Alison Abbott
Journal:  Nature       Date:  2003-06-19       Impact factor: 49.962

5.  The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program.

Authors:  J S McCombs; M B Nichol; G L Stimmel
Journal:  Value Health       Date:  1999 Jul-Aug       Impact factor: 5.725

6.  Long-term costs of treatment for depression: impact of drug selection and guideline adherence.

Authors:  W H Crown; M Treglia; L Meneades; A White
Journal:  Value Health       Date:  2001 Jul-Aug       Impact factor: 5.725

7.  Children with prepubertal-onset major depressive disorder and anxiety grown up.

Authors:  M M Weissman; S Wolk; P Wickramaratne; R B Goldstein; P Adams; S Greenwald; N D Ryan; R E Dahl; D Steinberg
Journal:  Arch Gen Psychiatry       Date:  1999-09

8.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.

Authors:  E Aguglia; M Casacchia; G B Cassano; C Faravelli; G Ferrari; P Giordano; P Pancheri; L Ravizza; M Trabucchi; F Bolino
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

View more
  33 in total

Review 1.  Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

Authors:  Robert D Gibbons; J John Mann
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Daniel H Solomon; Jyotsna Mehta; Colin Dormuth; Matthew Miller; Jennifer C Lee; Philip S Wang
Journal:  Arch Gen Psychiatry       Date:  2010-05

Review 3.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

4.  Antidepressants and youth: healing or harmful?

Authors:  Sara Markowitz; Alison Cuellar
Journal:  Soc Sci Med       Date:  2007-03-19       Impact factor: 4.634

Review 5.  [Antidepressants and suicidality. Risk-benefit analysis].

Authors:  U Hegerl
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

6.  Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide.

Authors:  Robert D Gibbons; Eisuke Segawa; George Karabatsos; Anup K Amatya; Dulal K Bhaumik; C Hendricks Brown; Kush Kapur; Sue M Marcus; Kwan Hur; J John Mann
Journal:  Stat Med       Date:  2008-05-20       Impact factor: 2.373

Review 7.  The use of antidepressants to treat depression in children and adolescents.

Authors:  Amy H Cheung; Graham J Emslie; Taryn L Mayes
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

8.  News coverage of FDA warnings on pediatric antidepressant use and suicidality.

Authors:  Colleen L Barry; Susan H Busch
Journal:  Pediatrics       Date:  2009-12-07       Impact factor: 7.124

9.  Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression.

Authors:  Vishal Bali; Michael L Johnson; Hua Chen; Marc L Fleming; Holly M Holmes; Rajender R Aparasu
Journal:  Ann Pharmacother       Date:  2015-11-25       Impact factor: 3.154

Review 10.  Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.

Authors:  Corrado Barbui; Eleonora Esposito; Andrea Cipriani
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.